Suppr超能文献

利尿剂对易卒中型自发性高血压大鼠心脏肥大的影响。

Diuretic effects on cardiac hypertrophy in the stroke prone spontaneously hypertensive rat.

作者信息

Contard F, Glukhova M, Marotte F, Narcisse G, Schatz C, Swynghedauw B, Guez D, Samuel J L, Rappaport L

机构信息

U127 INSERM, Hôpital Lariboisière, Paris, France.

出版信息

Cardiovasc Res. 1993 Mar;27(3):429-34. doi: 10.1093/cvr/27.3.429.

Abstract

OBJECTIVE

The aim was to compare the effects of two diuretics, indapamide and hydrochlorothiazide, on cardiac hypertrophy in stroke prone spontaneously hypertensive rats (SHR-SP).

METHODS

Six week old SHR-SP, on a 1% sodium chloride water intake, were treated with oral indapamide (3 mg.kg-1 x d-1) or hydrochlorothiazide (20 mg.kg-1 x d-1) over a 44 d period. The hypertrophic process was evaluated by classical indices and by the morphological analysis of myocyte cross sectional area, coronary artery thickness, and immunohistochemical analysis of interstitial fibrosis.

RESULTS

In the untreated SHR-SP on 1% sodium chloride, all animals developed severe hypertension and cardiac hypertrophy when compared to normotensive salt loaded WKY by 13 weeks of age. In salt loaded SHR-SP treated with indapamide or hydrochlorothiazide, systolic blood pressure was moderately decreased by the end of the treatment when compared with untreated SHR-SP, at 259(7) and 245(7) mm Hg respectively, v 300(11) mm Hg, p < or = 0.05. Myocyte enlargement appears to be the main feature involved in the development of cardiac hypertrophy in the SHR-SP. By the end of treatment both indapamide and hydrochlorothiazide prevented the development of cardiac hypertrophy evaluated by heart weight to body weight ratio [4.69(0.07) and 4.61(0.08) respectively, v 5.39(0.13), p < or = 0.001] and myocyte hypertrophy (-33% and -21% of the SHR-SP values, p < or = 0.001). Myocardial interstitial fibrosis and perivascular fibrosis were practically absent in the two treated groups.

CONCLUSIONS

Our results allow the characterisation of SHR-SP cardiac hypertrophy and indicate that the two types of chronic diuretic treatment prevent SHR-SP cardiac hypertrophy with a drug specific efficiency.

摘要

目的

比较两种利尿剂吲达帕胺和氢氯噻嗪对易卒中自发性高血压大鼠(SHR-SP)心脏肥大的影响。

方法

6周龄的SHR-SP,饮用含1%氯化钠的水,在44天的时间里口服吲达帕胺(3毫克·千克⁻¹·天⁻¹)或氢氯噻嗪(20毫克·千克⁻¹·天⁻¹)进行治疗。通过经典指标以及对心肌细胞横截面积、冠状动脉厚度的形态学分析和间质纤维化的免疫组织化学分析来评估肥大过程。

结果

在饮用1%氯化钠的未治疗SHR-SP中,与正常血压且摄入盐分的WKY相比,到13周龄时所有动物都出现了严重高血压和心脏肥大。在用吲达帕胺或氢氯噻嗪治疗的摄入盐分的SHR-SP中,与未治疗的SHR-SP相比,治疗结束时收缩压适度降低,分别为259(7)和245(7)毫米汞柱,而未治疗的为300(11)毫米汞柱,p≤0.05。心肌细胞增大似乎是SHR-SP心脏肥大发展的主要特征。治疗结束时,吲达帕胺和氢氯噻嗪均通过心脏重量与体重比[分别为4.69(0.07)和4.61(0.08),而SHR-SP为5.39(0.13),p≤0.001]和心肌细胞肥大(分别为SHR-SP值的-33%和-21%,p≤0.001)预防了心脏肥大的发展。两个治疗组中几乎不存在心肌间质纤维化和血管周围纤维化。

结论

我们的结果明确了SHR-SP心脏肥大的特征,并表明两种类型的慢性利尿治疗以药物特异性效率预防了SHR-SP心脏肥大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验